Regulus Therapeutics (RGLS) News Today → It's time to ween off Chinese lithium! (From Smallcaps Daily) (Ad) Free RGLS Stock Alerts $2.23 0.00 (0.00%) (As of 06/7/2024 08:52 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 4, 2024 | prnewswire.comRegulus Therapeutics Announces Expected Addition to the Russell 3000® and Russell 2000® IndexesJune 4, 2024 | americanbankingnews.comRegulus Therapeutics Inc. (NASDAQ:RGLS) Receives $7.25 Consensus PT from AnalystsJune 1, 2024 | marketbeat.comRegulus Therapeutics Inc. (NASDAQ:RGLS) Given Average Recommendation of "Moderate Buy" by BrokeragesRegulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) has been given an average recommendation of "Moderate Buy" by the five research firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and four have issued a bMay 16, 2024 | finanznachrichten.deRegulus Therapeutics Inc.: Regulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical OfficerMay 16, 2024 | prnewswire.comRegulus Therapeutics Announces Promotion of Rekha Garg, M.D., M.S., to Chief Medical OfficerMay 13, 2024 | theguardian.comStarwatch: the moon celebrates with a cruise past RegulusMay 12, 2024 | marketbeat.comRegulus Therapeutics Inc. (NASDAQ:RGLS) Short Interest Down 32.9% in AprilRegulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) saw a large decline in short interest in the month of April. As of April 30th, there was short interest totalling 4,210,000 shares, a decline of 32.9% from the April 15th total of 6,270,000 shares. Based on an average daily volume of 3,040,000 shares, the days-to-cover ratio is presently 1.4 days. Approximately 7.3% of the shares of the company are short sold.May 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Regulus Therapeutics Amid Positive Clinical Advances for RGLS8429May 10, 2024 | finanznachrichten.deRegulus Therapeutics Inc.: Regulus Therapeutics Reports First Quarter 2024 Financial Results and Recent UpdatesMay 9, 2024 | msn.comRGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q1 2024May 9, 2024 | prnewswire.comRegulus Therapeutics Reports First Quarter 2024 Financial Results and Recent UpdatesMay 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Regulus’s Innovative ADPKD Therapy RGLS8429May 6, 2024 | marketbeat.comRegulus Therapeutics' (RGLS) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $9.00 price target on shares of Regulus Therapeutics in a research note on Monday.May 6, 2024 | prnewswire.comRegulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)April 30, 2024 | prnewswire.comRegulus Therapeutics to Participate in the Canaccord Genuity Genetic Medicine for Generalists Webcast SeriesApril 27, 2024 | marketbeat.comVivo Capital LLC Acquires New Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS)Vivo Capital LLC bought a new position in shares of Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 5,000,000 shares of the biopharmaceutical company'sApril 10, 2024 | seekingalpha.comRegulus: It Is Finding Its Stride Despite Initial Setback In Targeting ADPKDMarch 28, 2024 | markets.businessinsider.comBuy Rating on Regulus’s RGLS8429 Backed by Positive Phase 1b Data and Unmet ADPKD Treatment NeedsMarch 27, 2024 | marketbeat.comShort Interest in Regulus Therapeutics Inc. (NASDAQ:RGLS) Expands By 9,244.3%Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) was the target of a large growth in short interest in the month of March. As of March 15th, there was short interest totalling 5,130,000 shares, a growth of 9,244.3% from the February 29th total of 54,900 shares. Currently, 13.0% of the shares of the company are sold short. Based on an average daily trading volume, of 2,870,000 shares, the short-interest ratio is currently 1.8 days.March 26, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Regulus Therapeutics Amid Promising Drug Development MilestonesMarch 25, 2024 | marketbeat.comRegulus Therapeutics (NASDAQ:RGLS) Given "Buy" Rating at HC WainwrightHC Wainwright restated a "buy" rating and issued a $9.00 price target on shares of Regulus Therapeutics in a research note on Monday.March 23, 2024 | finance.yahoo.comRegulus Therapeutics Inc (RGLS) Reports Year-End Earnings, Highlights Key Clinical AdvancementsMarch 22, 2024 | finanznachrichten.deRegulus Therapeutics Inc.: Regulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent UpdatesMarch 21, 2024 | investorplace.comRGLS Stock Earnings: Regulus Therapeutics Misses EPS for Q4 2023March 21, 2024 | finance.yahoo.comRegulus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent UpdatesMarch 19, 2024 | markets.businessinsider.comBuy Rating Affirmed for Regulus Therapeutics on Promising RGLS8429 ADPKD Treatment DataMarch 15, 2024 | finance.yahoo.comRGLS Mar 2024 7.500 putMarch 14, 2024 | finance.yahoo.comBiotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & MoreMarch 13, 2024 | markets.businessinsider.comRegulus’s Stock RGLS: Hold Rating Amidst Promising Yet Preliminary ADPKD Study Results and Financial PositionMarch 12, 2024 | marketwatch.comRegulus Therapeutics Shares Soar on Funding, Study DataMarch 12, 2024 | markets.businessinsider.comRegulus Surges 60% On Positive Outcome From Phase1b MAD Trial, Private Placement Of $100 MlnMarch 12, 2024 | msn.comWhy Is Kidney Disease-Focused Regulus Therapeutics Stock Trading Higher On Tuesday?March 12, 2024 | marketbeat.comTrading was temporarily halted for "RGLS" at 11:03 AM with a stated reason of "LULD pause." Trading set to resume at 11:03 AM. March 12, 2024 | msn.comConsumer Prices Tick Higher in February as US Equity Futures Turn Mixed Pre-BellMarch 12, 2024 | markets.businessinsider.comRegulus Announces $100 Mln Private Placement, Positive Data From Phase 1b MAD Trial Of RGLS8429March 12, 2024 | prnewswire.comRegulus Therapeutics Announces Oversubscribed $100 Million Private Placement of EquityMarch 12, 2024 | prnewswire.comRegulus Therapeutics Announces Positive Topline Data from the Second Cohort of Patients in its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)February 16, 2024 | money.usnews.comRegulus Therapeutics IncJanuary 3, 2024 | msn.comRegulus concludes enrolment in Phase I trial’s third cohort for ADPKDJanuary 2, 2024 | finance.yahoo.comRegulus Therapeutics Announces Completion of Enrollment in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)December 27, 2023 | seekingalpha.comRegulus Therapeutics files for $150M mixed shelfDecember 23, 2023 | morningstar.comRegulus Therapeutics Inc RGLSNovember 22, 2023 | finance.yahoo.comRegulus Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx ConferenceNovember 11, 2023 | markets.businessinsider.comRegulus Stock Maintains Buy Rating Amid Financial Stability and Positive Clinical Trial ProgressNovember 9, 2023 | finance.yahoo.comRegulus Therapeutics Reports Third Quarter 2023 Financial Results and Recent UpdatesNovember 2, 2023 | finance.yahoo.comRegulus Therapeutics Announces First Patient Dosed in Third Cohort of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)October 19, 2023 | finance.yahoo.comRegulus Therapeutics Advances to Cohort 3 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)October 5, 2023 | nasdaq.comRegulus Therapeutics (RGLS) Price Target Increased by 13.64% to 6.38September 22, 2023 | msn.comCanaccord Genuity Maintains Regulus Therapeutics (RGLS) Buy RecommendationSeptember 21, 2023 | markets.businessinsider.comAnalyst Expectations for Regulus Therapeutics's Future Get Regulus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter. Email Address You won't believe what Citigroup just did to it's depositors (Ad)The FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st This guide shows you what to do next. In a cashless society, Biden forces you to use the government's new "digital dollar"... CLICK HERE TO GET YOUR GUIDE NOW RGLS Media Mentions By Week RGLS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RGLS News Sentiment▼0.000.76▲Average Medical News Sentiment RGLS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RGLS Articles This Week▼21▲RGLS Articles Average Week Get Regulus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for RGLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Alimera Sciences News Lexicon Pharmaceuticals News Agenus News Vanda Pharmaceuticals News Emergent BioSolutions News XOMA News Codexis News Achieve Life Sciences News Rigel Pharmaceuticals News Sangamo Therapeutics News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RGLS) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | SponsoredNvidia needs this one obscure firm In my new investigation, I detail why this is the single most important factor in the future of AI. I expla...Porter & Company | Sponsored